This CPB has been revised to state that concomitant use of eliglustat (Cerdelga), imiglucerase (Cerezyme), taliglucerase alfa (Elelyso), velaglucerase alfa (VPRIV), and/or miglustat (Zavesca) is considered experimental and investigational for Gaucher disease or for any other indication because the safety and efficacy of concomitant use has not been established.